ARQ 197: Clinical Trial for Patients with Alveolar Soft Part Sarcoma

The purpose of this phase 2 study is to determine the overall response rate in patients with unresectable locally advanced or metastatic alveolar soft parts sarcoma, clear cell sarcoma or translocation associated renal cell carcinoma. The study will enroll adolescent (age 13 or older) and adult patients with a histologically or cytologically confirmed MiT malignant disease. Eligible patients will receive ARQ 197 twice daily. Treatment will be continued until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.

ARQ 197 is an oral drug in the family of targeted therapies. It is c-Met inhibitor, an investigational drug.

For more information click the following links:

1.   The National Institutes of Health

2.  ArQule, the biotech company that develops ARQ197

——————————————————————————————

The GVAX Cancer Vaccine Clinical Trial for ASPS patients is ongoing, but not recruiting participants anymore. This clinical trial was opened at the Dana-Farber Cancer Institute, Boston (click the following links for more information)

1. Announcement of the ASPS Clinical Trial on the US National Institute of Health

2. Important information for ASPS patients who want to join the Cancer Vaccine Clinical Trial at The Dana- Farber Cancer Institute, Boston

3. The GVAX Cancer Vaccine Trial at the Dana Farber Cancer Institute - Details